vTv Therapeutics (VTVT) Projected to Announce Earnings on Thursday

vTv Therapeutics (NASDAQ:VTVT) is projected to issue its results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.98) per share for the quarter.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.51. The company had revenue of ($0.02) million for the quarter.

vTv Therapeutics Stock Up 0.2%

NASDAQ VTVT opened at $35.10 on Thursday. The stock has a market cap of $138.29 million, a P/E ratio of -10.48 and a beta of 0.44. The company’s 50-day simple moving average is $36.18 and its 200 day simple moving average is $29.26. vTv Therapeutics has a twelve month low of $14.00 and a twelve month high of $44.00.

Hedge Funds Weigh In On vTv Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at $221,000. 683 Capital Management LLC acquired a new stake in vTv Therapeutics during the 4th quarter worth $731,000. Finally, Geode Capital Management LLC lifted its holdings in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after acquiring an additional 12,896 shares in the last quarter. 17.51% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on VTVT shares. HC Wainwright restated a “buy” rating and set a $47.00 target price (up from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. BTIG Research reaffirmed a “buy” rating and issued a $49.00 target price on shares of vTv Therapeutics in a research note on Wednesday. Roth Mkm initiated coverage on shares of vTv Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $58.00 price target for the company. TD Cowen assumed coverage on shares of vTv Therapeutics in a research note on Monday, January 5th. They set a “buy” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $55.25.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.